Fimlab Laboratories, Finland’s largest provider of laboratory services, research, and training, is taking the next step on its digital pathology journey with Proscia, a global leader in AI-enabled pathology solutions for precision medicine. The company will use Proscia’s software platform to help its pathologists generate more precise results with artificial intelligence (AI).
Digital pathology is driving a shift to data-rich images, each containing billions of pixels that provide one of the most detailed and direct profiles of diseases like cancer. While laboratories initially adopted digital pathology to drive efficiency gains, they are now realising added value by leveraging AI to unlock insights from this data that advance precision medicine.
“Artificial intelligence is beginning to solve many of pathology’s biggest challenges,” said Teemu Tolonen MD PhD, Chief Physician of Fimlab’s pathology department. “We carefully evaluated multiple software platforms and are confident Proscia’s will enable us to achieve a great impact from AI. Its open approach ensures we can leverage a broad variety of applications in our routine operations.”
With its intuitive user experience, robust functionality, and scalability, Proscia’s software can drive all aspects of Fimlab’s daily work. Pathologists will use the platform’s AI-enabled workflows to make more consistent interpretations of the most common types of cancer and drive efficiency. This includes running applications from Proscia’s growing precision medicine AI portfolio.
“Fimlab is one of the most innovative laboratories in the world,” said David West, Proscia’s CEO. “Its team is now advancing to the forefront of AI-enabled pathology with our software, and we are incredibly excited to see the impact of our work together.”